Elan Shares Climb on $3.25B Biogen's Tysabri Deal

Feb. 6 (Bloomberg) -- Bloomberg's Caroline Hyde reports on what is next for Elan Corp. as Biogen Idec Inc. agreed to acquire the company's stake in the multiple sclerosis drug Tysabri for $3.25 billion in cash plus future royalties. She speaks on Bloomberg Television's "The Pulse."
Bullard: Fed Rate Raising Tools Should Be Effective
29:48 - Federal Reserve Bank of St. Louis President James Bullard discusses the importance of inflation expectations and the tools the Federal Reserve has available to help monetary policy . He speaks from the Jackson Hole economic symposium in Jackson Hole, Wyoming on "Bloomberg Surveillance." (Source: Bloomberg)
  • Sweden's iZettle Planning to Expand in Europe: De Geer
  • What You Need to Know for Friday's Market
  • Greek Opposition Warns of Election Turmoil